<DOC>
	<DOCNO>NCT00205478</DOCNO>
	<brief_summary>The purpose study assess clinical activity safety two dose VX-702 compare placebo subject moderate severe Rheumatoid Arthritis .</brief_summary>
	<brief_title>Phase 2 Clinical Study Rheumatoid Arthritis With Investigational Oral p38 MAP Kinase Inhibitor VX-702</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adults active rheumatoid arthritis great 6 month evidence inflammation . Subjects condition preclude use cytokine inhibitor subject require DMARDs hydroxychloroquine sulfasalazine exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>